AVITA Medical Inc
NASDAQ:RCEL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AVITA Medical Inc
NASDAQ:RCEL
|
US |
|
Shinyoung Securities Co Ltd
KRX:001720
|
KR |
|
A
|
Australian Unity Office Fund
ASX:AOF
|
AU |
|
Qoria Ltd
ASX:QOR
|
AU |
|
PB Holding N.V.
AEX:PBH
|
NL |
|
Bourse Direct SA
F:BD6
|
FR |
|
Aeffe SpA
MIL:AEF
|
IT |
|
No Signboard Holdings Ltd
SGX:1G6
|
SG |
|
G
|
Graphisoft Park SE Ingatlanfejleszto Europai Rt
F:GUV
|
HU |
|
Indah Prakasa Sentosa Tbk PT
IDX:INPS
|
ID |
|
Gem Diamonds Ltd
LSE:GEMD
|
UK |
|
P
|
Proactis SA
PAR:PROAC
|
FR |
|
Shanta Gold Ltd
LSE:SHG
|
GG |
|
Alzamend Neuro Inc
NASDAQ:ALZN
|
US |
|
Studio Alice Co Ltd
TSE:2305
|
JP |
|
Residential Secure Income PLC
LSE:RESI
|
UK |
|
Tengda Construction Group Co Ltd
SSE:600512
|
CN |
|
Tamburi Investment Partners SpA
MIL:TIP
|
IT |
|
E
|
Euro Cervantes SOCIMI SA
MAD:YEUR
|
ES |
|
Spexis AG
SIX:SPEX
|
CH |
|
Nova Eye Medical Ltd
ASX:EYE
|
AU |
|
American Hotel Income Properties REIT LP
TSX:HOT.UN
|
CA |
|
Gemilang International Ltd
HKEX:6163
|
MY |
|
Nexstar Media Group Inc
NASDAQ:NXST
|
US |
AVITA Medical Inc
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California. The company went IPO on 2012-03-18. The firm is engaged in developing and commercializing a technology platform, which enables point-of-care autologous skin restoration for multiple unmet needs. The company provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its RECELL Autologous Cell Harvesting System (RECELL) enables clinicians to prepare Spray-On Skin Cells, an autologous skin cell suspension, which is sprayed onto the patient to regenerate natural healthy skin. The RECELL System is a single use disposable, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators to achieve the disaggregation and delivery of skin cells. The platform technology of the RECELL System allows for the preparation and delivery of Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s own skin cells.
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California. The company went IPO on 2012-03-18. The firm is engaged in developing and commercializing a technology platform, which enables point-of-care autologous skin restoration for multiple unmet needs. The company provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its RECELL Autologous Cell Harvesting System (RECELL) enables clinicians to prepare Spray-On Skin Cells, an autologous skin cell suspension, which is sprayed onto the patient to regenerate natural healthy skin. The RECELL System is a single use disposable, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators to achieve the disaggregation and delivery of skin cells. The platform technology of the RECELL System allows for the preparation and delivery of Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s own skin cells.
Revenue: AVITA Medical reported Q4 revenue of $17.6 million and full-year revenue of $71.6 million, up 11% over 2024 and in line with guidance.
2026 Guidance: Management expects 2026 revenue between $80 million and $85 million, representing 12% to 19% growth, reflecting normalization of RECELL utilization and broader portfolio use.
Reimbursement Clarity: 6 of 7 Medicare administrative contractors have now published payment rates for RECELL, removing a key headwind and restoring clinician confidence.
Cost Control: Operating expenses declined by 9% for the year, driven mainly by lower sales and marketing costs and supported by operating discipline.
Gross Margins: Full-year gross margin was 82.1%, down from 85.8% in 2024, mainly due to product mix and inventory reserves, but still above 80%.
Debt Refinancing: The company refinanced its debt in January, lowering minimum cash covenants and removing restrictive conditions, providing more flexibility.
Product Adoption: Growth is focused on increasing product utilization within existing accounts, with early signs of clinicians using RECELL alongside Cohealyx and PermeaDerm.
Utilization Focus: Management emphasized predictable, repeat usage of their products over new account additions to drive growth.
